Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oncology Conference Coverage — Stay Ahead in the Oncology Domain with Real-time Coverage from AACR, ESMO, ASCO, ASH, EHA, and Others | DelveInsight ...
-
Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study Ramat Gan, Israel, Dec. 30,...
-
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...
-
TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (FSE: B4IF) (the “Company” or “Goliath”) is pleased to announce it has increased the previously...
-
New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs. Nal-IRI/5FU/LV...
-
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with...
-
FORT MYERS, Fla., June 04, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), one of the nation’s fastest-growing networks of community oncology practices, is pleased to...
-
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...
-
Erste Daten aus einer laufenden Phase-2-Studie zeigten eine 12-Monats-Gesamtüberlebensrate von 69 % und ein medianes Gesamtüberleben von 17,5 Monaten bei Patientinnen und Patienten mit vorbehandeltem,...
-
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic...